Visterra
Company

Last deal

$23.6M

Amount

Series C

Stage

05.10.2017

Date

3

all rounds

$125.39M

Total amount

date founded

Financing round

General

About Company
Visterra develops therapeutic and diagnostic products for infectious diseases.

Industry

Sector :

Subsector :

Also Known As

Parasol Therapeutics, Visterra, Inc.

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Visterra, a clinical-stage biopharmaceutical company, specializes in the research and development of therapeutic and diagnostic products for infectious diseases. Using their proprietary technology platform, the company designs and engineers precision antibody-based product candidates that specifically bind to and modulate key disease targets. Visterra's novel platform is based on an understanding of glycobiology and glycochemistry, which allows for structure-based design of therapeutics and diagnostic platforms. The company's most advanced program is in Phase 2 clinical development, and they have established partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Globavir

Globavir

Globavir is a developer of therapeutics and diagnostics for the treatment of global infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care

Location

Los Altos, CA, USA

total rounds

4

total raised

$11.5M
AltPep

AltPep

AltPep is a biomedical startup revolutionizing the diagnosis and treatment of amyloid diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Mercer Island, WA 98040, USA

total rounds

3

total raised

$120.45M
Caraway Therapeutics

Caraway Therapeutics

Rheostat Therapeutics is a bio therapeutics company that develops novel drugs to treat neurodegenerative diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

3

total raised

$23M
AsclepiX Therapeutics

AsclepiX Therapeutics

AsclepiX Therapeutics is a biotech company that develops novel therapeutics for retinal diseases and cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Baltimore, MD, USA

total rounds

3

total raised

$50M
M&A Details
1

Acquired by

Otsuka Pharmaceutical

announced date

11.07.2018

price

$430M

Financials

Funding Rounds
9
3

Number of Funding Rounds

$125.39M

Money Raised

Their latest funding was raised on 05.10.2017. Their latest investor Merck Research Laboratories. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Alexandria Venture Investments

Alexandria Venture Investments

Alexandria Venture Investments is a venture capital firm that invests in real estate technology and healthcare sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Finance, Real Estate Investment

Location

Pasadena, CA, USA

count Of Investments

193

count Of Exists

7
Polaris Partners

Polaris Partners

Polaris Partners is a venture capital firm that invests in healthcare and technology companies at all stages of growth.

Sector

General Industrials

Subsector

Diversified Industrials

Location

Boston, MA, USA

count Of Investments

557

count Of Exists

135
MRL Ventures Fund

MRL Ventures Fund

Merck's MRL Ventures is investing in breakthrough science to develop new medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Financial Services, Venture Capital, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

total raised

$18.74M

count Of Investments

32

count Of Exists

2
Bill & Melinda Gates Foundation

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is a philanthropic organization.

Sector

Industrial Support Services

Subsector

Professional Business Support Services

Keywords

Non-Profit

Location

New York, NY, USA

count Of Investments

283

count Of Exists

13
Flagship Pioneering

Flagship Pioneering

Flagship Pioneering creates and grows ventures to transform health and sustainability.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

count Of Investments

219

count Of Exists

49
Co-Investors
Investors
14
5

Number of lead investors

14

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B, Series C
No
Series C
Merck Research Laboratories

Merck Research Laboratories

Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Boston, MA, USA

count Of Investments

3

count Of Exists

1
Alexandria Venture Investments

Alexandria Venture Investments

Alexandria Venture Investments is a venture capital firm that invests in real estate technology and healthcare sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Finance, Real Estate Investment

Location

Pasadena, CA, USA

count Of Investments

193

count Of Exists

7
Vertex Ventures HC

Vertex Ventures HC

Vertex Ventures HC is a venture capital company that invests in healthcare startups.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Palo Alto, CA, USA

count Of Investments

30

count Of Exists

4

People

Founders
2
Ram Sasisekharan
Ram Sasisekharan

Ram Sasisekharan

current job

Tychan
Tychan

organization founded

4

Ram Sasisekharan

Kevin Bitterman
Kevin Bitterman

Kevin Bitterman

Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics). He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice. Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.

current job

Atlas Venture
Atlas Venture

Kevin Bitterman

Employee Profiles
24

Kevin Spielberger

Antibody alchemist

Taizo Yoshida

Associate director, strategic planning and corporate development at visterra inc

Susan Sloan

Executieve director, translational

William Tubbs

Head of regulatory affairs

Melissa Thompson

Global head regulatory affairs

James Myette

Director, research at visterra inc

Kristin Narayan

Senior scientist

Patricia Vollmer

Senior director of manufacturing

Activity

Recent News
1